TheArchitect,
True, I worded it poorly. It was more about the company comparison and related price upside (i.e. RGS uses autologous donors for specific cell reparation purposes whilst reducing GVHD risk whereas CYP manufactures "blank cells" for any cell development and assignment whilst virtually removing GVHD risk) giving CYP an unlimited upside potential.
By the way I don't see MSB as a comparative company as it still depends on heterogeneous donor material but from a pure price perspective perhaps if I said MSB it would excite more in here...
Make more sense now?
Bidding war?, page-42
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 26.5¢ | 24.5¢ | $29.84K | 119.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 28000 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 73392 | 3 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |